奥拉帕利、贝伐珠单抗联合铂类化疗方案治疗卵巢癌的临床研究  

Clinical study of olaparil,bevacizumab and platinum chemotherapy regimen for ovarian cancer

作　　者：李向平 赵卿阁 王润芝 Li Xiangping;Zhao Qingge;Wang Runzhi(Oncology Department,The 989th Hospital of the Joint Logistics Support Force,Luoyang Henan,471000,China;Cadre ward,The 989th Hospital of the Joint Logistics Support Force,Luoyang Henan,471000,China)

机构地区：[1]联勤保障部队第九八九医院肿瘤科,河南洛阳471000 [2]联勤保障部队第九八九医院干部病房,河南洛阳471000

出　　处：《中外女性健康研究》2024年第8期40-43,共4页Women＇s Health Research

摘　　要：目的:探讨奥拉帕利、贝伐珠单抗联合铂类化疗方案治疗卵巢癌的临床研究。方法:选取联勤保障部队第九八九医院2021年7月至2024年1月收治的卵巢癌患者90例,利用倾向性评分匹配法按1∶1比例匹配后得到研究组和对照组各45例。对照组给予贝伐珠单抗联合顺铂、紫杉醇化疗,研究组在此基础上给予奥拉帕利片口服治疗,均治疗4个疗程。比较两组客观缓解率(ORR)和治疗前后血清血管生成素-2(Ang-2)、血管内皮生长因子(VEGF)、人附睾蛋白4(HE4)、免疫指标水平和用药期间药毒副反应发生率。结果:研究组ORR为68.89%,高于对照组的44.44%(P<0.05);治疗后,研究组VEGF、Ang-2和HE4水平均显著低于对照组(P<0.05);研究组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)高于对照组(P<0.05);两组各项毒副反应发生率均无显著差异(P>0.05)。结论:奥拉帕利、贝伐珠单抗联合铂类化疗治疗可有效提高卵巢癌患者近期疗效,改善血管内皮相关因子和免疫功能指标水平,安全性尚可控。Objective:To investigate the clinical study of olaparil and bevacizumab combined with platinum chemotherapy for ovarian cancer.Methods:A total of 90 ovarian cancer patients admitted to the 989th Hospital of the Joint Logistics Support Force from July 2021 to January 2024 were selected,and 45 cases were obtained in the study group and the control group,respectively,by using the propensity score matching method in a 1:1 ratio.The control group was given bevacizumab combined with cisplatin and paclitaxel chemotherapy,and the study group was given olapalil tablets orally,all for four courses.Objective response rates(ORR)and pre-and post-treatment serum angiogenin-2(Ang-2),vascular endothelial growth factor(VEGF),human epididymal protein 4(HE4),immune index level,and the incidence of toxic side effects during medication were compared.Results:The ORR of the study group was 68.89%,higher than the control group of 44.44%(P<0.05);after treatment,VE GF,Ang-2,and HE4 were significantly lower than the study group(P<0.05);CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than the study group(P<0.05);There was no significant difference in the incidence of toxic side effects between the two groups(P>0.05).Conclusion:Olaapil and bevacizumab combined with platinum chemotherapy can effectively improve the recent efficacy of ovarian cancer patients,improve the level of endothelium-related factors and immune function indicators in blood vessels,and the safety is controllable.

关 键 词：卵巢癌 奥拉帕利 贝伐珠单抗 铂类化疗 血管内皮相关因子 

分 类 号：R737.31[医药卫生—肿瘤]